Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications

NCT00443872 is registered in ClinicalTrials.gov with Parkinson's Disease and Movement Disorder Center of Boca Raton as lead sponsor.

NCT NCT00443872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00443872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications
Lead sponsor
Parkinson's Disease and Movement Disorder Center of Boca Raton
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2007
Completion date
December 31, 2008
Enrollment
77 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease